Literature DB >> 2502128

Inhibition of sorbitol formation in human erythrocytes by calcium dobesilate.

M Schmidt1, M Michal.   

Abstract

The effects of calcium dobesilate (Doxium, a drug already known to prevent or reverse the retinal microvascular lesions of diabetes mellitus) on sorbitol formation in human erythrocytes was studied, and compared with the effects of tetramethylene glutaric acid (TMGA), a specific aldose reductase inhibitor. Both compounds inhibited sorbitol formation. In a 29 mmol/l glucose medium, calcium dobesilate in concentrations of 2 and 10 mmol/l caused, 50 and 100% inhibition of sorbitol formation, respectively, whereas TMGA completely inhibited sorbitol formation at a concentration of 0.1 mmol/l. These results suggest that calcium dobesilate may exert, at least in part, its beneficial effect on diabetic microangiopathy by inhibiting the formation of sorbitol. The inhibition of sorbitol synthesis may be mediated by an inhibitory action of calcium dobesilate on aldose reductase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502128

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy.

Authors:  E B Leite; M C Mota; J R de Abreu; J G Cunha-Vaz
Journal:  Int Ophthalmol       Date:  1990-03       Impact factor: 2.031

2.  Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study.

Authors:  Maria L Ribeiro; Andras I Seres; Angela M Carneiro; Michael Stur; Alain Zourdani; Patricia Caillon; José G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

3.  Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries.

Authors:  Javier Angulo; Pedro Cuevas; Argentina Fernández; Sonia Gabancho; Sebastián Videla; Iñigo Sáenz de Tejada
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.